254 related articles for article (PubMed ID: 36892360)
1. Narrative Review of Drug-Associated Nail Toxicities in Oncologic Patients.
Emvalomati A; Oflidou V; Papageorgiou C; Kemanetzi C; Giannouli M; Kalloniati E; Efthymiadis K; Koukoutzeli C; Timotheadou E; Trigoni A; Patsatsi A; Lazaridou E; Apalla Z; Trakatelli M
Dermatol Pract Concept; 2023 Jan; 13(1):. PubMed ID: 36892360
[TBL] [Abstract][Full Text] [Related]
2. Nail toxicity induced by cancer chemotherapy.
Gilbar P; Hain A; Peereboom VM
J Oncol Pharm Pract; 2009 Sep; 15(3):143-55. PubMed ID: 19171552
[TBL] [Abstract][Full Text] [Related]
3. [Cutaneous adverse events to systemic anticancer therapies : Hand-foot syndrome and nail changes].
Ugurel S; Pföhler C; Gutzmer R
Dermatologie (Heidelb); 2024 Jun; 75(6):451-458. PubMed ID: 38802652
[TBL] [Abstract][Full Text] [Related]
4. Incidence of Adverse Cutaneous Reactions to Epidermal Growth Factor Receptor Inhibitors in Patients with Non-Small-Cell Lung Cancer.
Gisondi P; Geat D; Mattiucci A; Lombardo F; Santo A; Girolomoni G
Dermatology; 2021; 237(6):929-933. PubMed ID: 33508823
[TBL] [Abstract][Full Text] [Related]
5. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
Sibaud V
Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
[TBL] [Abstract][Full Text] [Related]
6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous Toxicities in Breast Cancer Patients Receiving Chemotherapy and Targeted Agents--An Observational Clinical Study.
Anoop TM; Joseph P R; Pn M; Kp P; Gopan G; Chacko S
Clin Breast Cancer; 2021 Aug; 21(4):e434-e447. PubMed ID: 33608219
[TBL] [Abstract][Full Text] [Related]
8. Nail toxicities induced by systemic anticancer treatments.
Robert C; Sibaud V; Mateus C; Verschoore M; Charles C; Lanoy E; Baran R
Lancet Oncol; 2015 Apr; 16(4):e181-9. PubMed ID: 25846098
[TBL] [Abstract][Full Text] [Related]
9. Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails.
Lacouture M; Sibaud V
Am J Clin Dermatol; 2018 Nov; 19(Suppl 1):31-39. PubMed ID: 30374901
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous manifestations of nontargeted and targeted chemotherapies.
Shi VJ; Levy LL; Choi JN
Semin Oncol; 2016 Jun; 43(3):419-25. PubMed ID: 27178698
[TBL] [Abstract][Full Text] [Related]
11. European recommendations for management of immune checkpoint inhibitors-derived dermatologic adverse events. The EADV task force 'Dermatology for cancer patients' position statement.
Apalla Z; Nikolaou V; Fattore D; Fabbrocini G; Freites-Martinez A; Sollena P; Lacouture M; Kraehenbuehl L; Stratigos A; Peris K; Lazaridou E; Richert B; Vigarios E; Riganti J; Baroudjian B; Filoni A; Dodiuk-Gad R; Lebbé C; Sibaud V
J Eur Acad Dermatol Venereol; 2022 Mar; 36(3):332-350. PubMed ID: 34910332
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous Toxicities of Molecular Targeted Therapies.
Stanculeanu DL; Zob D; Toma OC; Georgescu B; Papagheorghe L; Mihaila RI
Maedica (Bucur); 2017 Jan; 12(1):48-54. PubMed ID: 28878837
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Literature Review.
Apalla Z; Papageorgiou C; Lallas A; Delli F; Fotiadou C; Kemanetzi C; Lazaridou E
Dermatol Pract Concept; 2021 Jan; 11(1):e2021155. PubMed ID: 33614223
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane.
Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
J Am Acad Dermatol; 2015 Feb; 72(2):203-18; quiz 219-20. PubMed ID: 25592338
[TBL] [Abstract][Full Text] [Related]
15. Dermatologic adverse events to chemotherapeutic agents, Part 2: BRAF inhibitors, MEK inhibitors, and ipilimumab.
Choi JN
Semin Cutan Med Surg; 2014 Mar; 33(1):40-8. PubMed ID: 25037257
[TBL] [Abstract][Full Text] [Related]
16. Nail Changes With Chemotherapeutic Agents and Targeted Therapies.
Mittal S; Khunger N; Kataria SP
Indian Dermatol Online J; 2022; 13(1):13-22. PubMed ID: 35198463
[TBL] [Abstract][Full Text] [Related]
17. [Cutaneous side effects of targeted cancer drugs].
Below J; Homey B; Gerber PA
Hautarzt; 2017 Jan; 68(1):12-18. PubMed ID: 27885401
[TBL] [Abstract][Full Text] [Related]
18. Dermatologic immune-related adverse events: The toxicity spectrum and recommendations for management.
Apalla Z; Rapoport B; Sibaud V
Int J Womens Dermatol; 2021 Dec; 7(5Part A):625-635. PubMed ID: 35005180
[TBL] [Abstract][Full Text] [Related]
19. Cutaneous toxicities from targeted therapies used in oncology: Literature review of clinical presentation and management.
Huynh Dagher S; Blom A; Chabanol H; Funck-Brentano E
Int J Womens Dermatol; 2021 Dec; 7(5Part A):615-624. PubMed ID: 35024416
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous drug eruptions associated with the use of new oncological drugs.
Belloni B; Schönewolf N; Rozati S; Goldinger SM; Dummer R
Chem Immunol Allergy; 2012; 97():191-202. PubMed ID: 22613863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
